Hinova Pharmaceuticals Inc. (SHA:688302)
China · Delayed Price · Currency is CNY 40.05
-0.95 (-2.32%)
At close: Jun 2, 2026
Hinova Pharmaceuticals Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 46.22 | 20.19 | - | - | - | - |
Other Revenue | 0.28 | 0.28 | 0.37 | - | 1.65 | - |
| 46.5 | 20.47 | 0.37 | - | 1.65 | - | |
Revenue Growth (YoY) | 12574.70% | 5480.11% | - | - | - | - |
Cost of Revenue | 0.33 | 0.28 | 0.34 | - | 0.77 | - |
Gross Profit | 46.17 | 20.19 | 0.03 | - | 0.88 | - |
Selling, General & Admin | 97.08 | 80.15 | 53.49 | 88 | 97.04 | 80.28 |
Research & Development | 117.32 | 112.71 | 174.03 | 248.27 | 251.37 | 264.93 |
Other Operating Expenses | -1.26 | 0.84 | 0.41 | 0.42 | 0.35 | 0.06 |
Operating Expenses | 212.55 | 193.7 | 227.94 | 336.69 | 348.75 | 345.27 |
Operating Income | -166.38 | -173.51 | -227.91 | -336.69 | -347.87 | -345.27 |
Interest Expense | -0.21 | -0.35 | -0.53 | -1.49 | -3.92 | -2.56 |
Interest & Investment Income | 11.05 | 13.58 | 19.16 | 28.62 | 22.5 | 26.97 |
Currency Exchange Gain (Loss) | -1.65 | -1.65 | 1.35 | 1.4 | 7.56 | -2.1 |
Other Non Operating Income (Expenses) | -2.28 | -0.75 | -0.43 | -0.38 | -0.17 | -0.14 |
EBT Excluding Unusual Items | -159.47 | -162.68 | -208.35 | -308.53 | -321.9 | -323.11 |
Gain (Loss) on Sale of Investments | 9.58 | 10.17 | 3.96 | 8.35 | 10.27 | -1.5 |
Gain (Loss) on Sale of Assets | - | - | - | -0.01 | -0 | -0 |
Other Unusual Items | 14.86 | 15.27 | 4.91 | 6.04 | 10.12 | 18.44 |
Pretax Income | -135.03 | -137.25 | -199.48 | -294.14 | -301.51 | -306.18 |
Income Tax Expense | 0 | 0 | 0.01 | 0.02 | - | - |
Earnings From Continuing Operations | -135.03 | -137.25 | -199.5 | -294.16 | -301.51 | -306.18 |
Net Income | -135.03 | -137.25 | -199.5 | -294.16 | -301.51 | -306.18 |
Net Income to Common | -135.03 | -137.25 | -199.5 | -294.16 | -301.51 | -306.18 |
Shares Outstanding (Basic) | 99 | 99 | 99 | 99 | 91 | 74 |
Shares Outstanding (Diluted) | 99 | 99 | 99 | 99 | 91 | 74 |
Shares Change (YoY) | -1.18% | -0.51% | 0.21% | 9.06% | 22.21% | 5.74% |
EPS (Basic) | -1.37 | -1.39 | -2.01 | -2.97 | -3.32 | -4.12 |
EPS (Diluted) | -1.37 | -1.39 | -2.01 | -2.97 | -3.32 | -4.12 |
Free Cash Flow | -149.21 | -191.76 | -276.63 | -354.68 | -384.13 | -247.6 |
Free Cash Flow Per Share | -1.51 | -1.94 | -2.79 | -3.58 | -4.23 | -3.33 |
Gross Margin | 99.29% | 98.62% | 8.43% | - | 53.57% | - |
Operating Margin | -357.85% | -847.65% | -62127.45% | - | -21072.49% | - |
Profit Margin | -290.42% | -670.51% | -54382.81% | - | -18264.53% | - |
Free Cash Flow Margin | -320.91% | -936.81% | -75410.46% | - | -23269.07% | - |
EBITDA | -161.69 | -169.34 | -225.83 | -334.4 | -345.96 | -342.22 |
D&A For EBITDA | 4.7 | 4.17 | 2.07 | 2.28 | 1.91 | 3.05 |
EBIT | -166.38 | -173.51 | -227.91 | -336.69 | -347.87 | -345.27 |
Revenue as Reported | 46.5 | 20.47 | 0.37 | - | 1.65 | - |